Association of apolipoprotein-CIII (apoC-III), endothelium-dependent vasodilation and peripheral neuropathy in a multi-ethnic population with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 72, Issue , 2017, Pages 75-82

  Pek, Sharon Li Ting ^a   Sum, Chee Fang ^a   Yeoh, Lee Ying ^a   Lee, Simon Biing Ming ^b   Tang, Wern Ee ^b   Lim, Su Chi ^a   Tavintharan, Subramaniam ^a  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

^b NATIONAL HEALTHCARE GROUP   (Singapore)

Author keywords

Apolipoprotein CIII; Diabetic peripheral neuropathy; Endothelial dysfunction; Endothelium dependent vasodilation; Type 2 diabetes

Indexed keywords

ALBUMIN; APOLIPOPROTEIN C3; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTIMATED GLOMERULAR FILTRATION RATE; ETHNIC GROUP; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDIAN; INSULIN BLOOD LEVEL; LASER DOPPLER FLOWMETRY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINE SAMPLING; VASCULAR ENDOTHELIUM; VASODILATATION; VERY ELDERLY; BLOOD; COMPLICATION; DIABETIC NEUROPATHIES; DYSLIPIDEMIA; ETHNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSIOLOGY;

AGED; APOLIPOPROTEIN C-III; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; HUMANS; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; VASODILATION;

EID: 85018321731     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2017.03.016     Document Type: Article

References (43)

1. [1] Fowler, M.J., Microvascular and macrovascular complications of diabetes. Clin Diabetes 26 (2008), 77–82.
2. [2] Zhou, J., Zhou, S., Inflammation: therapeutic targets for diabetic neuropathy. Mol Neurobiol, 2013, 1–11.
3. [3] Resnick, H.E., Vinik, A.I., Schwartz, A.V., Leveille, S.G., Brancati, F.L., Balfour, J., et al. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age: the Women's Health and Aging Study. Diabetes Care 23 (2000), 1642–1647.
4. [4] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 1998, 837–853.
5. [5] Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 1998, 854–865.
6. [6] The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329, 1993, 977–986.
7. [7] Stirban, A., Microvascular dysfunction in the context of diabetic neuropathy. Curr Diab Rep, 14, 2014, 541.
8. [8] Ginsberg, H.N., Insulin resistance and cardiovascular disease. J Clin Invest 106 (2000), 453–458.
9. [9] Wiggin, T.D., Sullivan, K.A., Pop-Busui, R., Amato, A., Sima, A.A., Feldman, E.L., Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58 (2009), 1634–1640.
10. [10] Chew, E.Y., Ambrosius, W.T., Davis, M.D., Danis, R.P., Gangaputra, S., Greven, C.M., et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363 (2010), 233–244.
11. [11] Drury, P.L., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 54 (2011), 32–43.
12. [12] Rajamani, K., Colman, P.G., Li, L.P., Best, J.D., Voysey, M., D'Emden, M.C., et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373 (2009), 1780–1788.
13. [13] Crosby, J., Peloso, G.M., Auer, P.L., Crosslin, D.R., Stitziel, N.O., Lange, L.A., et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 (2014), 22–31.
14. [14] Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Tybjaerg-Hansen, A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371 (2014), 32–41.
15. [15] Chen, M., Breslow, J.L., Li, W., Leff, T., Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res 35 (1994), 1918–1924.
16. [16] Klein, R.L., McHenry, M.B., Lok, K.H., Hunter, S.J., Le, N.A., Jenkins, A.J., et al. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism 53 (2004), 1296–1304.
17. [17] Klein, R.L., McHenry, M.B., Lok, K.H., Hunter, S.J., Le, N.A., Jenkins, A.J., et al. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications 19 (2005), 18–25.
18. [18] Pek, S.L., Tavintharan, S., Wang, X., Lim, S.C., Woon, K., Yeoh, L.Y., et al. Elevation of a novel angiogenic factor, leucine-rich-alpha2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J Clin Endocrinol Metab 100 (2015), 1586–1593.
19. [19] Liu, J.J., Yeoh, L.Y., Sum, C.F., Tavintharan, S., Ng, X.W., Liu, S., et al. Vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1, is associated with diabetic kidney disease in Asians with type 2 diabetes. J Diabetes Complications 29 (2015), 707–712.
20. [20] Tavintharan, S., Woon, K., Pek, L.T., Jauhar, N., Dong, X., Lim, S.C., et al. Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. Atherosclerosis 215 (2011), 176–179.
21. [21] Liu, J.J., Lim, S.C., Yeoh, L.Y., Su, C., Tai, B.C., Low, S., et al. Ethnic disparities in risk of cardiovascular disease, end-stage renal disease and all-cause mortality: a prospective study among Asian people with type 2 diabetes. Diabet Med 33 (2016), 332–339.
22. [22] Abbott, C.A., Malik, R.A., van Ross, E.R., Kulkarni, J., Boulton, A.J., Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 34 (2011), 2220–2224.
23. [23] Qamar, A., Khetarpal, S.A., Khera, A.V., Qasim, A., Rader, D.J., Reilly, M.P., Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol 35 (2015), 1880–1888.
24. [24] Atzmon, G., Rincon, M., Schechter, C.B., Shuldiner, A.R., Lipton, R.B., Bergman, A., et al. Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol, 4, 2006, e113.
25. [25] Caron, S., Verrijken, A., Mertens, I., Samanez, C.H., Mautino, G., Haas, J.T., et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 31 (2011), 513–519.
26. [26] van Hoek, M., van Herpt, T.W., Dehghan, A., Hofman, A., Lieverse, A.G., van Duijn, C.M., et al. Association of an APOC3 promoter variant with type 2 diabetes risk and need for insulin treatment in lean persons. Diabetologia 54 (2011), 1360–1367.
27. [27] Brahimaj, A., Ligthart, S., Ikram, M.A., Hofman, A., Franco, O.H., Sijbrands, E.J., et al. Serum levels of apolipoproteins and incident type 2 diabetes: a prospective cohort study. Diabetes Care 40 (2017), 346–351.
28. [28] Avall, K., Ali, Y., Leibiger, I.B., Leibiger, B., Moede, T., Paschen, M., et al. Apolipoprotein CIII links islet insulin resistance to beta-cell failure in diabetes. Proc Natl Acad Sci U S A 112 (2015), E2611–E2619.
29. [29] Digenio, A., Dunbar, R.L., Alexander, V.J., Hompesch, M., Morrow, L., Lee, R.G., et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care 39 (2016), 1408–1415.
30. [30] Ooi, E.M., Chan, D.T., Watts, G.F., Chan, D.C., Ng, T.W., Dogra, G.K., et al. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res 52 (2011), 794–800.
31. [31] Lin, J., Khetarpal, S.A., Terembula, K., Reilly, M.P., Wilson, F.P., Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol, 16, 2015, 130.
32. [32] Wang, C.S., McConathy, W.J., Kloer, H.U., Alaupovic, P., Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 75 (1985), 384–390.
33. [33] Ito, Y., Azrolan, N., O'Connell, A., Walsh, A., Breslow, J.L., Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249 (1990), 790–793.
34. [34] Masucci-Magoulas, L., Goldberg, I.J., Bisgaier, C.L., Serajuddin, H., Francone, O.L., Breslow, J.L., et al. A mouse model with features of familial combined hyperlipidemia. Science 275 (1997), 391–394.
35. [35] Ikeda, T., Sugiuchi, H., Senba, U., Shibuya, Y., Uji, Y., Okabe, H., et al. Preliminary findings on the variation of serum apolipoprotein levels in neural degenerative disorders. J Clin Lab Anal 7 (1993), 1–4.
36. [36] Roustit, M., Loader, J., Deusenbery, C., Baltzis, D., Veves, A., Endothelial dysfunction as a link between cardiovascular risk factors and peripheral neuropathy in diabetes. J Clin Endocrinol Metab 101 (2016), 3401–3408.
37. [37] Chapouly, C., Yao, Q., Vandierdonck, S., Larrieu-Lahargue, F., Mariani, J.N., Gadeau, A.P., et al. Impaired hedgehog signalling-induced endothelial dysfunction is sufficient to induce neuropathy: implication in diabetes. Cardiovasc Res 109 (2016), 217–227.
38. [38] Zheng, C., Azcutia, V., Aikawa, E., Figueiredo, J.L., Croce, K., Sonoki, H., et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 34 (2013), 615–624.
39. [39] Kawakami, A., Aikawa, M., Alcaide, P., Luscinskas, F.W., Libby, P., Sacks, F.M., Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114 (2006), 681–687.
40. [40] Li, H., Han, Y., Qi, R., Wang, Y., Zhang, X., Yu, M., et al. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. Cardiovasc Res 107 (2015), 579–589.
41. [41] Coppey, L.J., Gellett, J.S., Davidson, E.P., Dunlap, J.A., Lund, D.D., Yorek, M.A., Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50 (2001), 1927–1937.
42. [42] Lauria, G., Hsieh, S.T., Johansson, O., Kennedy, W.R., Leger, J.M., Mellgren, S.I., et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 17 (2010), 903–912 [e44-9].
43. [43] Boulton, A.J., Vinik, A.I., Arezzo, J.C., Bril, V., Feldman, E.L., Freeman, R., et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28 (2005), 956–962.